Reuters logo
BRIEF-Obsidian Therapeutics Announces $49.5 Mln Series A Financing To Develop Controllable Cell And Gene Therapy Products
December 6, 2017 / 11:22 AM / 7 days ago

BRIEF-Obsidian Therapeutics Announces $49.5 Mln Series A Financing To Develop Controllable Cell And Gene Therapy Products

Dec 6 (Reuters) - Takeda Pharmaceutical Co Ltd:

* OBSIDIAN THERAPEUTICS ANNOUNCES $49.5 MILLION SERIES A FINANCING TO DEVELOP CONTROLLABLE CELL AND GENE THERAPY PRODUCTS

* OBSIDIAN THERAPEUTICS - SERIES A FINANCING LED BY GV, AND INCLUDED TAKEDA VENTURES, AMGEN VENTURES AMONG OTHERS Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below